Market evolution: Human vaccines (CN 300241) — 2015–2025
Introduction
This report analyzes the evolution of trade in human vaccines (Customs code 300241) by the European Union with non-EU countries from 2022 to 2025. The period, particularly its early years, was dominated by the unprecedented demand and global mobilization to produce and distribute vaccines against SARS-CoV-2 (COVID-19). The data reveals a market characterized by a massive initial surge in trade values driven by pandemic-era vaccines, followed by a significant contraction and normalization. The EU maintained a formidable position as a net exporter, though its trade surplus has decreased substantially from its peak. The analysis underscores the profound impact of the pandemic shock and the subsequent market adjustment.
1. The Pandemic-Driven Boom and Subsequent Contraction
The trade data for human vaccines is overwhelmingly defined by the trajectory of the COVID-19 pandemic. The initial years saw explosive growth in export values, primarily fueled by SARS-CoV-2 vaccines, which then gave way to a sharp decline as global demand patterns shifted.
1.1. The Peak of the Pandemic Vaccine Trade
The year 2022 represented the apex of EU vaccine exports in value terms. Total exports reached a high of €36.94 billion. This was driven overwhelmingly by exports of SARS-CoV-2 vaccines (CN 30024110), which constituted over 58% of all vaccine export value that year. Imports also peaked in 2023, reaching €6.86 billion, though at a level far below exports, reinforcing the EU's strong net exporter status.
1.2. The Normalization and Decline
By 2025, the market had undergone a profound correction. Total vaccine exports fell to €16.78 billion, a decrease of 54.6% from 2022. This decline was led by the collapse of SARS-CoV-2 vaccine trade; their export value in 2025 was €2.40 billion, an 89% drop from its 2022 peak. Consequently, the EU's trade surplus in vaccines shrank from €30.37 billion in 2022 to €12.85 billion in 2025.
| Metric | 2022 (Peak) | 2025 | Change (2022–2025) |
|---|---|---|---|
| EU Export Value | €36.94 B | €16.78 B | -54.6% |
| EU Import Value | €6.57 B | €3.93 B | -40.2% |
| EU Trade Balance | €30.37 B | €12.85 B | -57.7% |
Source: General Overview
2. Shifting Trade Patterns and Geographic Concentration
The pandemic not only scaled trade volumes but also reshaped key trade relationships and increased market concentration, particularly on the export side.
2.1. Dramatic Shifts in Key Partner Relationships
The value traded with major partners experienced extreme volatility. Exports to the United States, the EU's largest partner, remained relatively stable, declining only 14.6% from 2022 to 2025. In contrast, exports to Japan and China fell by over 90%, reflecting the sharp wind-down of pandemic-era supply contracts. On the import side, the EU's reliance on India for vaccines plummeted by 98.2%, while imports from the United States increased by 6.9%, solidifying its role as the primary source.
2.2. Increased Concentration in EU Export Markets
The concentration of the EU's vaccine exports, as measured by the Herfindahl-Hirschman Index (HHI), more than doubled from 1,196 in 2022 to 2,463 in 2025. This indicates a market that became more reliant on a narrower set of destination countries after the initial global scramble for vaccines. Belgium and the Netherlands consistently remained the dominant EU exporting countries, accounting for over 75% of export value in 2025.
2.3. The Evolving Role of EU Member States
Not all EU members followed the same trajectory. Belgium saw a substantial, though less severe, decline in exports compared to the EU average. Meanwhile, Italy increased its export value by 39.7% over the period, emerging as a more significant player. Specialization data for 2025 shows Ireland and Belgium as the most specialized EU exporters in vaccines, with high Revealed Comparative Advantage (RCA) indices of 16.78 and 2.27, respectively.
3. EU Autonomy and Market Vulnerabilities
Despite the post-pandemic contraction, key indicators suggest the EU has retained a strong structural position as a global vaccine producer and exporter, though certain vulnerabilities persist.
3.1. Robust Net Exporter Status and Production Base
The EU's net import reliance remained deeply negative throughout the period, moving from -167% in 2022 to -1,171% in 2025. This mathematically confirms its massive net exporter status. This is supported by a domestic production sector that saw its output quantity increase by 69.7% over the period, even as the value of production fell, indicating a focus on volume and likely a shift in the product mix post-pandemic.
3.2. High Trade Intensity and Export Propensity
The EU vaccine market exhibits exceptionally high trade intensity (106% in 2025) and export propensity (107% in 2025). This indicates that the production of human vaccines in the EU is fundamentally oriented toward the global market, making it a strategic export industry.
3.3. Persistent Import Vulnerabilities
While the EU is a net exporter, it is not immune to supply-side risks. Import volatility, measured by the coefficient of variation, was extremely high for suppliers like India (1.10) and South Africa (1.99), reflecting unstable sourcing patterns. Furthermore, the increased concentration of the export market (higher HHI) means the EU's vaccine industry is more vulnerable to demand shocks in a few key partner countries.
Conclusion
The 2022–2025 period for the EU human vaccine market was a story of extraordinary boom and subsequent adjustment, driven almost entirely by the COVID-19 pandemic. The market saw a record peak in trade values in 2022, fueled by SARS-CoV-2 vaccines, followed by a sharp contraction and return to a new, lower baseline by 2025. Throughout this upheaval, the EU solidified its position as the world's leading vaccine exporter, backed by a productive and highly specialized domestic industry. However, the normalization phase has also revealed new market characteristics: greater concentration in export destinations and continued reliance on a limited number of key partners. The challenge for the EU moving forward will be to leverage its strong production base to serve both ongoing global health needs and strategic autonomy, while managing the inherent volatility and concentration risks embedded in this critical sector.